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Abstract
Premature ovarian insufficiency (POI) is a heterogeneous disorder, affecting approximately 
1% of women before the age of 40. Heterogeneity of POI is reflected by various causes. 
The known causes are genetic defects, autoimmune ovarian damage, metabolic, iatrogenic 
following surgery, cancer therapy, and environmental factors. However, in most cases, the 
cause remains unknown (idiopathic POI). The main symptom is the absence of regular men-
strual cycles, and the diagnosis is confirmed by the raised gonadotropins and low estradiol. 
The disorder usually leads to infertility and has long-term comorbidities such as cardiovas-
cular diseases, osteoporosis, and cognitive impairments. Management includes the use of 
hormone replacement therapy till the age of natural menopause. In women having fertility 
issues, the spontaneous conception varies between 5 and 10%, and in vitro fertilization with 
donor oocytes remains the treatment of choice. Moreover, fertility preservation options can 
be offered to some patients with cancer and those at risk of early menopause, such as those 
with familial cases of POI. Further research is clearly needed, to identify new mechanisms 
which may improve the prediction of the early onset of the disease.
Keywords: premature ovarian insufficiency, irregular menstrual cycle, estrogen 
deficiency, hormone replacement therapy, infertility treatment
1. Introduction
Premature ovarian insufficiency (POI) is a heterogeneous condition defined by the presence 
of menopausal-level serum gonadotropins in repeated blood tests with menstrual distur-
bance (oligomenorrhea or amenorrhea) in adolescent girls or women under 40 years of age 
[1]. Several different terms have been used to describe this condition, such as premature 
menopause, premature ovarian insufficiency (POI), or premature ovarian failure (POF). 
Confusion exists concerning nomenclature, namely, the use of POF or POI. The term POI has 
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been adopted recently by the European Society of Human Reproduction and Embryology 
(ESHRE) consensus instead of “failure” [2]. Because it was found to more accurately describe 
the fluctuating nature of the condition. The POF is best considered as the only final stage of 
POI [3, 4]. The incidence of spontaneous POI has been estimated to affect 1 in 100 women 
before 40 years of age and 1 in 1000 women before 30 years of age [1, 5]. Although the inci-
dence of spontaneous POI appears to have remained stable, of increasing concern is the ris-
ing incidence of iatrogenic POI [6]. Improved survival following malignant diseases has led 
to increasing numbers of women experiencing the long-term effects of cancer treatments. A 
recent cohort study estimated the incidence of POI, both spontaneous and iatrogenic, at 7.4% 
[7]. The risk of POI varies by ethnicity, ranging from 0.1% in Japanese to 1% in Caucasian and 
1.4% in African American and Hispanic groups [8]. Environmental factors such as cigarette 
smoking and poverty were associated with an increased risk of idiopathic POI. In contrast, 
certain factors related to ovulation, such as late menarche, irregular menstruation, and longer 
breastfeeding seem to reduce the risk of POI [9]. The familial form of POI is rare, representing 
4–31% of all cases of POI [10–12]. Morris DH et al. (2011) reported that women were around 
six times more likely to have early menopause if their mother (odd ratio [OR], 6.2; p < 0.001) 
or older sister (OR, 5.5; p < 0.001) also experienced early menopause [13].
2. Objective
In this comprehensive review, we aim to provide an overview of the current knowledge of the 
identifiable causes leading to POI development and the recent advances in the management of 
its consequences in terms of long-term complications as well as in terms of infertility concerns.
3. Methods
Literature search strategy: Using the MEDLINE database and Google Scholar, we conducted 
a comprehensive literature search to identify relevant publications on menstrual cycle dis-
orders associated with premature ovarian insufficiency. The keyword combinations include 
“premature ovarian insufficiency,” “primary ovarian failure,” “hypergonadotropic amenor-
rhea,” “hypergonadotropic hypogonadism,” and “early menopause.”
Selection criteria: The search was restricted to articles that were published up to May 2018 in 
English language and that assessed at least one of the following aspects of the condition: 
“epidemiology,” “diagnosis,” “etiology,” “long-term consequences,” “hormonal replacement 
therapy,” “infertility management,” and “prediction.”
Data synthesis and analysis: The conclusions and the interpretation of the findings were based 
on our personal experience. In addition, we provided some clinical recommendations and 
guidelines about the management of patients experiencing premature or early menopause 
based on the expertise of prestigious scientific societies such as the European Society for 
Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive 
Medicine (ASRM). Statistical testing was not conducted.
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4. Diagnosis
Current studies have failed to determine specific biomarkers or signs/symptoms of POI that 
will accurately predict when menopause will occur. Some women with POI may not experi-
ence any specific symptoms particularly in the idiopathic form of the largest etiology, which 
may delay the establishment of the diagnosis.
One study reported that over 50% of patients with POI had seen at least three clinicians 
before the diagnosis was made, and in 25% the diagnosis took more than 5 years [14]. Before 
puberty, the clinical picture is characterized by absent menarche, and pubertal delay results 
in absent sexual maturation. After puberty, the typical disorder is characterized by the loss 
of menstrual regularity (oligomenorrhea or amenorrhea) in young women for 3 or more 
consecutive months and often associated with symptoms of estrogen deficiency such as 
vasomotor symptoms which are similar to those observed with the onset of menopause, 
such as hot flushes, insomnia, nervousness, irritability, loss of libido, vaginal dryness, dys-
pareunia, etc. Female infertility is a common concern, as only 5–10% of the patients will 
conceive spontaneously [15]. POI may be part of other syndromic features: autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy, blepharophimosis-ptosis-epican-
thus inversus syndrome, carbohydrate-deficient glycoprotein syndromes, galactosemia, 
Turner syndrome, and PHP I [16].
Additionally, patients can experience long-term consequences of hypoestrogenism, includ-
ing low bone density (osteoporosis) [17], cardiovascular diseases [18], and neurocognitive 
disorders [19]. For the biochemical confirmation, follicle-stimulating hormone (FSH) levels 
are used as the gold standard in establishing a diagnosis of POI. Two serum FSH levels in 
the menopausal range should be obtained at least a month apart (BOX 1) [27]. However, 
there is a lack of consensus on adequate cutoff levels used to define hypergonadotropism. 
No follicles were found in ovarian biopsies when FSH levels are above 33 and 40 mIU/ml 
in women with primary and secondary amenorrhea, respectively [20]. Some women with 
POI express FSH levels lower than these proposed cutoff values, particularly women with 
autoantibodies. La Marca et al. (2009) found that women with POI due to steroidogenic cell 
autoimmunity had significantly lower FSH levels (n = 26, median 37 mIU/ml) compared 
with idiopathic POI (median 99 mIU/ml) (P = 0.001) [21]. Furthermore, estradiol (E2) levels 
are typically low, with a level of 50 pg/ml in women with absent or nonfunctioning follicles 
[22]. Antimullerian hormone (AMH) is currently the most convenient predictor of ovarian 
reserve. Very low AMH levels  seem to play a role in predicting age at menopause [23, 24]. 
Younger than 40 years of age
Oligo/amenorrhea for at least 4 months
Two FSH levels in the menopausal range, obtained at least a month apart
Data from [27].
Box 1. Criteria to establish the diagnosis of premature ovarian insufficiency.
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The differential diagnosis is based on the exclusion of other causes of primary and secondary 
amenorrhea, for example, pregnancy, polycystic ovarian syndrome,  hypothalamic-pituitary 
disease (pituitary tumors, hyperprolactinemia, Kallmann syndrome), hypothalamic 
amenorrhea (induced by stress, intensive exercise, anorexia, weight loss, fasting, and 
severe diseases), endocrine disorders (hyperthyroidism, hypothyroidism, and Cushing 
syndrome), and vaginal/uterus anatomical abnormalities, such as Rokitansky syndrome or 
Asherman syndrome. Once the diagnosis has been confirmed, second-line investigations to 
look for an underlying cause should be considered which may have implications for the indi-
vidualization of the management Table 1 [25].
5. Etiology
Three potential mechanisms can be associated with POI, that is, a congenital decrease in pri-
mordial follicles, accelerated follicular atresia, and an inability to recruit primordial follicles 
[26]. The known causes of POI are wide ranging and can be divided into spontaneous and 
iatrogenic categories.
5.1. Spontaneous POI
Most cases of spontaneous POI are idiopathic despite the diagnostic advances [27] but may be 
also due to genetic causes, autoimmune disorders, metabolic dysfunction, enzyme deficien-
cies, toxins, or infections [27–29].
Test Implications
Positive test Negative test
Genetic/Chromosomal
Karyotyping
(for diagnosis of Turner syndrome)
Refer to endocrinologist, 
cardiologist and geneticist
A second analysis of the karyotype in 
epithelial cells (in case of high clinical 
suspicion)
Test for Y-chromosomal material Discuss gonadectomy with the 
patient
Fra-X Refer to geneticist
Autosomal genetic testing1
Antibodies2
ACA/21OH antibodies Refer to endocrinologist Re-test in case of clinical signs
TPO-Ab Test TSH every year or symptoms
1not at present indicated in women with POI, unless there is evidence suggesting a specific mutation (e.g. BPES).
2POI of unknown cause or if an immune disorder is suspected.
Data from [25].
Table 1. Summary of diagnostic workup.
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5.1.1. Genetic causes of POI
The normal ovarian function requires the presence of many intact genes functionally normally 
and in a coordinated fashion. Chromosomal abnormalities are found in around 10–12% of 
women with POI, of which the majority is X chromosomal abnormalities [30]. An increasing 
number of studies have documented autosomal involvement. The incidence of chromosomal 
abnormalities is higher in women with primary amenorrhea (21%) than in those presenting 
with secondary amenorrhea (11%) [31].
5.1.1.1. X Chromosome defects
Both the short and long arms of the X chromosome appear to play important roles.
X Chromosome defects usually involve either complete deletion of one X (Turner syn-
drome) or partial deletions, duplications, and balanced translocations between the X and 
autosomal chromosomes. Females lacking an X chromosome as well as those showing 
an extra X chromosome are predisposed to developing POI. Monosomy X (45X), known 
as Turner syndrome, is due to the loss of the second sex chromosome and affects 1 in 
2500 live-born female infants and has a frequency of 4–5% in POI [32]. In phenotypic 
women, Turner syndrome is associated with short stature, gonadal dysgenesis, and pri-
mary amenorrhea. In women with Tuner syndrome, oocyte loss usually begins early in 
childhood as a result of accelerated follicle atresia [33]. The vast majority of pregnancies 
with this karyotype end in spontaneous miscarriage, and it is argued that the surviving 
individuals most likely carry some degree of mosaicism [34]. In mosaic Turner syndrome 
(45X/46XX), patients have a milder phenotype and may present later with secondary 
amenorrhea and hypergonadotropic hypogonadism. Trisomy X (47XXX) is caused by 
nondisjunction of the X chromosome during meiosis. It is the most common form of 
aneuploidy, occurring in 1:900 women. About 1.5–3.8% patients with POI had the triple 
X [30, 35] and may manifest in many mosaic forms, that is, 45X/47XXX, 46XX/47XXX, or 
47XXX/48XXXX [36]. The presence of three X chromosomes presumably leads to mei-
otic disturbance and, secondarily, ovarian failure. X Chromosome deletions associated 
with POI are more common than translocations. At present, the microdeletions are not 
normally identified by conventional karyotyping and so often go unrecognized. Krauss 
et al. reported in 1987 a family in which one woman and two girls, with early menopause, 
had a deletion of the long arm of the X chromosome (Xq21–Xq27) [37]. Cytogenetic and 
molecular analyses of POI women carrying a balanced X-autosome translocation allowed 
the identification of a “critical region” for the ovarian development and function on the 
long arm of the X chromosome from Xq13.3 to q27. Various deletions or translocations 
occurring within this region and also on the short arm of the X chromosome have been 
associated with POI [38, 39]. POI can also be associated with the Xq isochromosome 
which occurs when the centromere splits abnormally in the transverse plane instead of 
the longitudinal plane. The resulting chromosome pair contains structurally identical 
arms with identical genes. The isochromosome for the long arm (q) is the most common X 
structural abnormality. These patients present with streak gonads and Turner-like char-
acteristics which are rare causes of POI [40].
Premature Ovarian Insufficiency
http://dx.doi.org/10.5772/intechopen.80090
101
5.1.1.2. Single-gene defects
The fragile X syndrome is an X-linked dominant genetic disorder that is a leading cause of 
mental retardation and autism. Women exhibiting extended repeats of the CGG trinucleotide 
sequence may be classified as having the permutation (55–199 repeats) or the full condition 
(>200 repeats). There is an association, although nonlinear, between the number of repeats 
and the severity of the condition. The fragile site of the X chromosome contains a (CGG) 
repeat in the 5′ region of the gene. In normal variants, the trinucleotide repeat ranges from 6 
to 55 repeats.
The syndrome occurs when the number of the repeats exceeds 200, being denominated as 
full mutation alleles. The fragile X mental retardation 1 (FMR1) gene premutation, mapped 
at position Xq27.3 on the X chromosome, is the most frequently identified single-gene muta-
tion associated with POI outside the Xq POI critical region. It has been shown that females 
carrying a premutation have up to 23% rate of POI and experience menopause 5 years earlier 
than average [41]. The FMR1 premutation has been identified in 11% of familial POI and 
3% of sporadic cases [42–44], and therefore, screening for the FMR1 premutation is usually 
recommended in women diagnosed with POI to identify those patients and family members 
who may be at risk of having children with fragile X syndrome. Those with identified pre-
mutation should be referred for family genetic counseling. The bone morphogenetic protein 15 
gene (BMP15) is a member of transforming growth factor beta (TGF-ß) superfamily and is located 
on the short arm of the X chromosome (Xp11.2) within the Xp POI critical region [45, 46]. It is an 
oocyte-specific folliculogenesis growth differentiation factor (GDF) and appears to have a vital role in 
folliculogenesis and granulosa cell growth.
Approximately 1.5–12% of POI is associated with BMP15 gene mutation [47–50].
Fragile site, folic acid type, rare (FRAXE)/fragile site mental retardation 2 gene (FMR2) has 
been described in patients who have the cytogenetic changes of fragile X syndrome but who 
are FMR1 mutation negative. It was found at Xq28 and found to be folate sensitive [51].
5.1.1.3. Autosomal genetic defects
While several genes relevant to ovarian function lie on the X chromosome, autosomal genes 
also appear to be involved in the development of POI [26].
In recent years, attention has focused on genes that are known to play a role in folliculo-
genesis and ovarian function. Oocyte-specific gene expression is necessary for primordial 
follicle formation and their subsequent differentiation into primary follicles. A number 
of autosomal genes have been suggested as a causative factor of POI. For some of these 
genes, mutations are identified, while others are listed as candidate genes with a need 
for further investigation. The genes with identified mutations that could result in POI are 
genes involved in folliculogenesis (NR5A1, NOBOX, FIGLA, and FOXL2), folliculogen-
esis growth factors (GDF9 and inhibin A), sex hormone function (CYP17A1, CYP19, FSH/
luteinizing hormone (LH) receptors, and NR5A1) [26, 38], or genes identified in syndromes 
often associated with POI such as Bloom syndrome BLM 15q26.1 [52], Ataxia telangiectasia, 
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A-T. ATM 11q22-q23 [53], Werner syndrome WRN 8p12 [54], and Rothmund-Thomson syn-
drome RTS 8q24.3 [55]. Given that the conventional approaches have had limited success in 
finding causative genes, further research and new techniques on the genetic background of 
POI including genome-wide analysis in affected families may change this recommendation 
in the near future.
5.1.2. Autoimmune causes of POI
Anti-ovarian antibodies are reported in POI by several studies, but their specificity and 
pathogenic role are questionable. Autoimmune diseases are estimated to be involved in the 
pathogenesis of up to 5% of POI cases. Adrenal autoimmunity is thought to account for 
60–80% of autoimmune POI [56], and there is a strong association between the presence of 
adrenal antibodies and a diagnosis of autoimmune lymphocytic oophoritis [57]. The evidence 
of oophoritis is rare (<3%) in POI in the absence of adrenal involvement [16]. The presence 
of many other autoantibodies has been investigated such as ovarian and other steroidogenic 
cell autoantibodies; however, reliable markers to diagnose non-adrenal autoimmunity are 
yet to be identified [56]. POI can be associated with endocrine (thyroid, hypoparathyroid, 
diabetes mellitus, and hypophysitis) and non-endocrine diseases (chronic candidiasis, idio-
pathic thrombocytopenic purpura, vitiligo, alopecia, autoimmune hemolytic anemia, perni-
cious anemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, Crohn’s disease, 
Sjogren syndrome, primary biliary cirrhosis, and chronic active hepatitis) (Table 2) [16, 58, 
59]. POI may be part of the autoimmune polyglandular syndromes (APS) when accompanied 
by other autoimmune endocrinopathies. POI is more common with APS types I and III than 
with APS type II [60].
5.1.3. Metabolic causes of POI
A number of inherited enzymatic pathway disorders have been associated with ovarian 
follicular dysfunction leading to POI such as galactose-1-phosphate uridylyltransferase 
deficiency (galactosemia) [61], 19, carbohydrate-deficient glycoprotein deficiency [62], 
17α-hydroxylase/17,20 desmolase deficiency [63], and aromatase mutations [64] where 
there is biochemical damage of the ovary and autoimmune regulator which triggers auto-
immune damage. However, the strength of evidence linking each anomaly with POI is 
variable.
Endocrine Hypo/hyperthyroidism, Hypoparathyroidism, Diabetes mellitus type II, Hypophysitis, Addison’s 
disease.
Non-endocrine Idiopathic thrombocytemic purpura, Chronic candidiasis, Vitiligo, Alopecia, Hemolytic or 
Pernicious anemia,
Systemic lupus erythematodes, Rheumatoid arthritis, Cirrhosis, Sjogren’s sy, Primary biliary 
cirrhosis, Chronic hepatitis etc.
Data from [16, 58, 59].
Table 2. Endocrine and non-endocrine diseases associated with premature ovarian failure.
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5.2. Induced POI
The induced POI may result from damage to the ovaries, such as that caused by iatrogenic 
agents like chemotherapy, radiotherapy, pelvic surgery, and also environmental toxic agents.
5.2.1. Cancer therapy
There is an overall increase in cancer prevalence followed by an increase in long-term survival 
of the affected patients these days compared to the past. The 5-year survival rate for child-
hood, adolescent, and young adult cancer currently exceeds 80% [65]. Medical treatment for 
neoplastic conditions can be associated with POI. Chemotherapy and radiotherapy are well-
documented causes of POI.
Chemotherapy induces apoptosis of mature ovarian follicles, and histological studies have 
shown fibrosis, vascular damage, and reduced follicle numbers. The gonadotoxic effect of 
chemotherapy is drug and dose dependent [66]. Alkylating agents have been shown to be 
gonadotoxic [67]. The prepubertal ovary is relatively resistant to this form of gonadotoxicity 
[67]. The risk of developing POI after radiotherapy is dependent on the radiation therapy field 
(abdominal pelvic, total body irradiation) and on dose and age [68–70]. Transposition of the 
ovaries in young women requiring pelvic irradiation helps in preserving their ovarian function.
5.2.2. Pelvic surgery
Aside from surgical menopause due to bilateral oophorectomy, limited evidence suggests 
that pelvic surgery is maybe associated with POI such as hysterectomy [71], tubal sterilization 
[72], or both ovarian surgery for endometrioma and endometriosis [73] presumably due to 
damage to ovarian blood vessels as a result of the surgical procedure. Research has now also 
linked ovarian drilling for polycystic ovary syndrome and removal of endometriotic cysts to 
an earlier age at menopause [74, 75].
5.2.3. Toxins
The increasing prevalence of POI in recent years might be also due to an increase in presently 
unidentified environmental toxic agents. However, studies examining the cause and effect of 
the chemical substances and POI in humans are rare.
Chang et al. (2007) found that cigarette smoking was associated with an increased risk of 
POI (OR = 1.82 [1.03–3.23]) [76]. Many other endocrine-disrupting substances have been also 
suggested to be ovotoxic and influencing the age of menopause such as 2-bromopropane [76], 
vinylcyclohexene diepoxide (VCD) [77], polycyclic aromatic hydrocarbons (PAHs) [77], etc., 
but they are not readily considered as diagnosable causes of POI. Further research is war-
ranted to clarify in which toxicants affect human reproduction and how insufficiency with 
FSH values is found in the menopausal range [78].
5.2.4. Infections
It has been indicated that many viral infections can be followed by POI, but only mumps 
oophoritis has been directly linked to POI, explaining 3–7% of POI cases [79]. Other potential 
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causes of POI include tuberculosis, malaria, varicella, and Shigella [80]. More recently, there 
has been suggestion that human immunodeficiency virus (HIV) infection (or antiviral ther-
apy) can lead to POI. However, a recent systematic review revealed nonconclusive evidence 
due to a significant methodological limitation with available data [81].
6. Management
Patients must be provided with adequate information (education, understanding, and 
counseling). Management should address the following aspects: psychology support, ovar-
ian hormone replacement for the prevention of long-term complications, and therapy for 
fertility.
6.1. Psychologic support
The diagnosis of POI is an extremely devastating psychologic disturbance [35]. Some will 
experience a range of emotions such as high levels of depression and low levels of self-esteem 
with negative effects on sexuality [82], and providers should offer support regarding infertil-
ity, altered self-image, and sexual dysfunction. Patients may benefit from referral to a psy-
chologist and support groups [83].
6.2. Hormone replacement therapy
Hormone replacement therapy (HRT) remains the cornerstone of treatment for relief of meno-
pausal symptoms (including vasomotor instability, sexual dysfunction, mood, fatigue, and 
skin issues) and prevention of long-term morbidity and earlier mortality related to prolonged 
estrogen deficiency [84]. The results of Women’s Health Initiative (WHI) study should not be 
applied to young women with POI [85, 86]. In contrast with women older than 50s, POI is a patho-
logic condition in which young women have low serum E2 levels compared with their peers. 
For young women with E2 deficiency, hormone therapy is indeed a “replacement,” whereas 
in women with normal menopause, hormone therapy is hormone “extension.” Physiological 
replacement of ovarian steroid hormones until the age of 50 years (the average age of natural 
menopause) is generally accepted as routine, unless a specific contraindication exists, such 
as an estrogen-dependent malignancy. At present, very little evidence exists regarding the 
optimum method of hormone replacement, and options include both the combined oral con-
traceptive pill (COC) and hormone replacement. Data regarding the optimal estradiol levels 
in POI are lacking; however, the average serum estradiol level during the menstrual cycle 
in normal women is approximately 100 pg/ml [87]. Transdermal and transvaginal replace-
ment of 100 μg/day of estradiol achieves physiologic blood levels in this range and provides 
adequate symptomatic relief. The transdermal route has the advantage of avoidance of first-
pass hepatic metabolism and appears to be free of an excess risk of thrombosis compared with 
oral estrogen [88–90]. To reduce the risk of endometrial hyperplasia, 5–10 mg of medroxy-
progesterone acetate should be given for 12 days of the month, provided that the uterus 
is present and intact [90, 91]. However, the optimum type of progestogen is unclear. With 
the use of this regimen, most of women will develop monthly withdrawal bleeding, which 
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may be psychologically important to the patient. The COC is also commonly used as hor-
mone replacement in POI. However, they should not be recommended as first-line hormone 
replacement. Indeed, they result in supraphysiological doses of sex steroid hormones and 
are associated with an increased risk of thromboembolic events related to the first-pass effect 
on the liver [27]. Androgen replacement could be carefully considered for women who have 
persistent fatigue and low libido despite optimized estrogen replacement [92]. Transdermal 
testosterone administration and dehydroepiandrosterone treatment are two of the options for 
androgen replacement in these women [93]. Importantly, this should be performed with great 
caution and for relatively short periods until more data are available. When there has been 
no spontaneous start to puberty or progression of breast development, many options for HRT 
are suggested for puberty induction. However, systemic administration of increasing doses 
of estradiol, preferably by transdermal application, is the only form of therapy to achieve 
natural levels of estradiol in blood and mimic normal estradiol physiology in adolescence 
and adulthood [94, 95]. Patients who do not want to get pregnant should be offered con-
traception due to the 5–10% chance of spontaneous conception. Women with untreated POI 
are at increased risk of developing long-term comorbidities such as cardiovascular disease 
[96], metabolic syndrome [97], osteoporosis, dementia, cognitive impairment, Parkinsonism, 
reduced sexual function, and psychological well-being. Untreated POI can induce specific 
increase in mortality rate due to complications of the prolonged estrogen deficiency compared 
to those with a menopause after the age of 50 years [98]. The main reason for shortened life 
expectancy in women with POI is cardiovascular disease. The Framingham study was one of 
the first to show a higher incidence of cardiovascular disease among postmenopausal women 
than age-matched women who were premenopausal [99]. A number of studies have subse-
quently demonstrated higher rates of coronary artery disease, higher rates of heart failure, 
and higher rates of mortality in women reaching menopause before 40–45 years of age, and 
it has been demonstrated that this impairment was reversed by estrogen replacement [100]. 
Compared with control women, women with premature ovarian insufficiency have reduced 
bone mineral density. The prevalence of osteoporosis in POI appears to be in the range of 
8–14% [101]. Multiple studies have shown that the lower bone mineral density (BMD) seen 
in women with POI is associated with significantly higher overall fracture risk, and this has 
been associated with the presence, degree, and duration of estrogen deficiency. Studies on 
fracture risk in early menopause compared to natural menopause have demonstrated that 
fracture rates are reduced among women with POI or early menopause who are treated with 
the use of HRT [101–103]. Early data demonstrate an increased risk of cognitive impairment 
[104]. Some studies suggest that estrogen is neuroprotective. The Mayo Clinic Cohort Study 
of Oophorectomy and Aging demonstrated that women who underwent either unilateral or 
bilateral oophorectomy before the onset of the menopause had an increased risk of cognitive 
impairment or dementia [105] and Parkinsonism [104] compared to controls and that this 
risk increased with younger age at oophorectomy. They also demonstrated a protective role 
for estrogen replacement in women with bilateral oophorectomy when taken until at least 
50 years of age. A similar finding was noted in a Danish cohort study, revealing an increased 
risk of dementia in women undergoing oophorectomy prior to the age of 50 years, with a 
similar trend of increasing risk with earlier age at oophorectomy [106].
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6.3. Fertility
6.3.1. Spontaneous conception and POI
For many women with POI, infertility is the most devastating aspect of the diagnosis.
Fertility of women with POI is severely diminished, but unlike menopause, POI may be 
accompanied with spontaneous ovarian activity and natural pregnancies in approximately 
5–10% [107]. Currently, no fertility treatment has been found to effectively increase fertility 
in women with POI including estrogens [108–110], 5-dehydroepiandrosterone (DHEA) [111], 
corticosteroids [112], and azathioprine [113].
6.3.2. Assisted reproductive technology (ART) and POI
6.3.2.1. Oocyte donation
The only proven therapy for obtaining a pregnancy in patients with POI is fertilization of a 
donor oocyte. At present IVF with donor oocytes confers the highest chance of pregnancy for 
women with POI with high success rates of around 40–50% per cycle.
The pregnancy rate from oocyte donation is not greatly affected by the recipient’s age [114, 115].
6.3.2.2. Fertility management of the Turner syndrome
There are special considerations regarding oocyte donation in women with Turner syndrome. 
If pregnancy is desired, hormone replacement therapy can be initiated to increase uterine 
size, followed by assisted reproductive technology, namely, in vitro fertilization with an 
oocyte donor. However, coexisting cardiac abnormalities associated with Turner syndrome 
may increase the risk of pregnancy for the mother, and therefore this type of approach to 
achieve pregnancy is strongly discouraged [116, 117]. Should a Y chromosome be identified 
with or without an SRY gene mutation, the patient should be counseled about the risk of 
development of a gonadal tumor, and gonadectomy should be advised [118, 119].
6.3.2.3. Fertility preservation and POI
Fertility preservation may also be considered for women at risk of POI; in young women 
who require cancer treatments, including chemotherapy, radiotherapy, and surgery; or for 
those who have a strong family history of POI. Options for fertility preservation include ovar-
ian transposition, oocyte or embryo cryopreservation, and ovarian tissue cryopreservation. 
Ovarian transposition remains the standard of care for women undergoing pelvic radiation, 
although it has been suggested that it may be combined with ovarian tissue cryopreservation. 
Embryo cryopreservation remains the most successful technique, with success rates approach-
ing that of fresh embryo transfer [120, 121]. Live birth rates of approximately 30% per embryo 
transfer have been reported, depending on the age of the patient [120]. The success of oocyte 
cryopreservation has also improved significantly in recent years, and birth rates similar to 
that of fresh oocytes have been reported [122]. Oocyte cryopreservation is a potential option 
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for women without a partner. Since the initial report of successful pregnancy following ovar-
ian tissue cryopreservation and subsequent transplant in 2000 [123], there has been increasing 
success with the technique [124, 125].
7. Prediction and genetic counseling
Contrary to the induced POI occurring in cancer survivors, the spontaneous POI particularly 
the idiopathic form is still difficult to be predicted in the general population. Low circulating 
AMH level is currently thought to be the most reliable measure of reduced ovarian reserve 
and may play a role in predicting age at menopause [23]. Sowers et al. (2008) have shown 
that AMH starts declining 5 years before the final menstrual period. All these observations 
suggest a potential role for AMH in screening women at high risk for POI and in well woman 
screening programs [24]. Autoantibody screening, for anti-adrenal, anti-ovarian, and antithy-
roid antibodies, is also recommended [25]. Genetic counseling is nowadays recommended 
for several reasons, when a genetic form of POI is suspected or identified. The prevalence of 
familial POI has been reported to be between 4 and 31% of cases in various series [126–129]. 
The early diagnosis of familial POI will provide the opportunity to predict the likelihood of 
early menopause and allow other reproductive choices to be made, such as freezing embryos 
or having children earlier. Karyotyping and screening for the FMR1 gene permutation are 
especially important in younger patients with or without mental retardation or when a female 
is born from a family with female members affected with POI. The review of McConkie-Rosell 
states that approximately 13–24% of women who are fragile X premutation carriers (identi-
fied through families with fragile X syndrome) have POI [130].
8. Future
Continued advances in DNA sequencing techniques will facilitate finding additional genes 
responsible for POI in other portions of the genome. Besides, the future holds the possibility 
of restoring ovarian function with ovarian or oogonial stem cell (OSC) therapy which may 
open the door to novel fertility preservation strategies for women with both age-related and 
POI [131]. More recently, Kawamura et al. (2013) have successfully promoted follicle growth, 
retrieved mature oocytes, and performed IVF. Following embryo transfer, a healthy baby 
was delivered [132]. This in vitro activation (IVA) approach has been reproduced by a group 
in Zhengzhou University, China, with two cases [133]. Up to the summer of 2018, there were 
more than one dozen of successful cases.
9. Summary
The POI represents a continuum of declining ovarian function with intermittent ovulation in 
women below the age of 40 years resulting usually in an earlier than average menopause. Its 
incidence is gradually increasing secondary to the improved survival of young women with 
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cancer. In most cases, the etiology is unknown, but known causes include genetic disorders, 
particularly involving the X chromosome, associations with autoimmune diseases, cancer 
therapy, pelvic surgery, and also environmental toxic agents. A timely diagnosis of POI is 
the main challenge. The typical disorder is characterized by the loss of regular menstrual 
cycles, and the diagnosis is confirmed by the detection of menopausal-level serum gonado-
tropins in repeated blood tests. Second-line investigations should be directed by specific 
clinical indications. Regardless of the etiology, patients with POI are estrogen deficient. The 
aims of HRT extend beyond simply symptom relief to levels that support cardiovascular, 
bone, and cognitive health. Only 5–10% of women with POI may conceive spontaneously. 
Currently, there are no proven treatments to improve ovarian function, and only the use 
of donor eggs with IVF confers the highest chance of pregnancy. However, in women with 
Turner syndrome, this approach is strongly discouraged. To date, the prediction of POI is 
difficult in the general population. However, in women at risk of POI particularly those who 
have a strong family history of POI, or require cancer treatments, a screening program will 
provide the opportunity to predict the likelihood of early onset menopause and to consider 
fertility preservation as well. Further research is needed particularly in idiopathic POI to 
identify mechanisms and specific molecular defects which may offer a better opportunity 
for early therapeutic interventions.
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